Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Roivant Sciences Ltd. or Novartis AG because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Roivant Sciences Ltd. and Novartis AG compare based on key financial metrics to determine which better meets your investment needs.

About Roivant Sciences Ltd. and Novartis AG

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Latest Biotechnology and Roivant Sciences Ltd., Novartis AG Stock News

As of September 4, 2026, Roivant Sciences Ltd. had a $25.2 billion market capitalization, compared to the Biotechnology median of $280.5 million. Roivant Sciences Ltd.’s stock is up 61% in 2026, up 0.6% in the previous five trading days and up 177.88% in the past year.

Currently, Roivant Sciences Ltd. does not have a price-earnings ratio. Roivant Sciences Ltd.’s trailing 12-month revenue is $7.5 million with a % net profit margin. Year-over-year quarterly sales growth most recently was -36.4%. Analysts expect adjusted earnings to reach $-1.580 per share for the current fiscal year. Roivant Sciences Ltd. does not currently pay a dividend.

As of September 4, 2026, Novartis AG had a $294.2 billion market cap, putting it in the 99th percentile of all stocks. Novartis AG’s stock is up 16% in 2026, up 4% in the previous five trading days and up 24.58% in the past year.

Currently, Novartis AG’s price-earnings ratio is 24.2. Novartis AG’s trailing 12-month revenue is $56.7 billion with a 22.5% net profit margin. Year-over-year quarterly sales growth most recently was 0.8%. Analysts expect adjusted earnings to reach $8.803 per share for the current fiscal year. Novartis AG currently has a 3.0% dividend yield.

How We Compare Roivant Sciences Ltd. and Novartis AG Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Roivant Sciences Ltd. and Novartis AG’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Roivant Sciences Ltd. and Novartis AG Stock Value Grades

Company	Ticker	Value
Roivant Sciences Ltd.	ROIV	na
Novartis AG	NVS	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Roivant Sciences Ltd. does not have a meaningful Value Score. Novartis AG has a Value Score of 27, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Roivant Sciences Ltd. or Novartis AG has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Roivant Sciences Ltd. or Novartis AG is the better investment when it comes to value.

Roivant Sciences Ltd. and Novartis AG’s Quality Grades

Company	Ticker	Quality
Roivant Sciences Ltd.	ROIV	F
Novartis AG	NVS	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Roivant Sciences Ltd. has a Quality Score of 14, which is Very Weak. Novartis AG has a Quality Score of 82, which is Very Strong.

The Quality Grade Winner: Novartis AG

As you can clearly see from the Quality Grade breakdown above, Novartis AG has a better overall quality grade than Roivant Sciences Ltd.. For investors who are looking for companies with higher quality than others in the same industry, Novartis AG could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Roivant Sciences Ltd. and Novartis AG’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Roivant Sciences Ltd.	ROIV	D
Novartis AG	NVS	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Roivant Sciences Ltd. has a Earnings Estimate Score of 31, which is Negative. Novartis AG has a Earnings Estimate Score of 55, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Roivant Sciences Ltd. or Novartis AG has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Roivant Sciences Ltd. or Novartis AG is the better investment when it comes to estimate revisions.

Other Roivant Sciences Ltd. and Novartis AG Grades

In addition to Quality, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Roivant Sciences Ltd. and Novartis AG pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Roivant Sciences Ltd. or Novartis AG Stock?

Overall, Roivant Sciences Ltd. stock has a Value Score of , Estimate Revisions Score of 31 and Quality Score of 14.

Novartis AG stock has a Value Score of 27, Estimate Revisions Score of 55 and Quality Score of 82.

Comparing Roivant Sciences Ltd. and Novartis AG’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.